Drug-Resistant Tuberculosis Challenges and Progress
Drug-Resistant Tuberculosis Challenges and Progress
复制标题
DOI：
10.1016/j.idc.2016.02.010
复制
发表时间：
2016-06-01
影响因子：
4.4
通讯作者：
Bark, Charles M.
中科院分区：
文献类型：
--
作者：
Kurz, Sebastian G.;Furin, Jennifer J.;Bark, Charles M.
抗生素耐药性是一个自然的进化过程，在结核分枝杆菌的情况下，这是基于自发的染色体突变，这意味着在监督治疗下提供的精心设计的联合药物方案将防止耐药菌株的出现。不幸的是，有限的资源、贫困和忽视导致了耐药结核病在世界各地的出现。国际社会对此提供了财政和科学支持，导致新的快速诊断方法、先进的临床开发中的新药和治疗方案，以及对耐药机制及其在结核病控制和治疗的各个方面的应用的日益深入的了解。
Antimicrobial resistance is a natural evolutionary process, which in the case of Mycobacterium tuberculosis is based on spontaneous chromosomal mutations, meaning that well-designed combination drug regimens provided under supervised therapy will prevent the emergence of drug resistant strains. Unfortunately, limited resources, poverty, and neglect have led to the emergence of drug-resistant tuberculosis throughout the world. The international community has responded with financial and scientific support, leading to new rapid diagnostics, new drugs and regimens in advanced clinical development, and an increasingly sophisticated understanding of resistance mechanisms and their application to all aspects of TB control and treatment.